Boehringer Ingelheim Licenses Drug Targets from Autoimmune Collaboration with BioFocus DPI
News Jul 18, 2008
This is the second milestone reached in this three-year collaboration, initially announced in January 2006. In the collaboration, BioFocus DPI applied its SilenceSelect® shRNA-based gene collection to run a target discovery screen for Boehringer Ingelheim’s autoimmune discovery research.
BioFocus DPI obtained upfront fees, research and development funding and will receive milestone fees when certain drug discovery criteria are met. Should all criteria on a target be achieved, total potential contract value for BioFocus DPI may exceed €2 million per target.
“We are delighted that targets identified through our shRNA screening approach have met Boehringer’s selection criteria,” said Onno van de Stolpe, Chief Executive Officer of Galapagos. “This is further testament that the target discovery research performed by BioFocus DPI meets the standards of the world’s leading pharmaceutical companies.”
4000-Year Old DNA Helps Track the Spread of Rice Farming in AsiaNews
Rice farming spread far and wide in ancient Southeast Asia, but how it got there has been a mystery. Now, a study of 4000-year-old DNA—a rare find in this region—suggests it came with farmers migrating from China, where rice farming originated.
Island Life: Worm-eating Mice Hold Clues to EvolutionNews
How much space does a population need to branch out and form a new species? A small island in the Philippines, and four species of mice that live on it, have helped researchers work out the answer.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Comments | 0 ADD COMMENT
Epigenetics in the nervous system: development and disease
Oct 01 - Oct 03, 2018